Schizophrenia in children causes severe mental illness affecting their emotional intelligence and greatly affects quality of life. The US Food and Drug Administration (FDA) has approved brexipiprazole for treating schizophrenia for patients aged 13-17 years.
REXULTI was approved in the U.S. in 2015 for the treatment of schizophrenia in adults and for adjunctive treatment of major depressive disorder in adults.Diagnosis of childhood schizophrenia involves ruling out other mental health disorders and determining that symptoms aren't due to alcohol or drug use, medication or a medical condition.
"We are proud to offer a treatment option for adolescents with schizophrenia who are navigating the complexities of their health during a transitional time in their lives – we hope this will help make a meaningful difference in reducing their schizophrenia symptoms so they can be their best," said Johan Luthman, executive vice president, R&D, Lundbeck.
For more information check out the full story on the link below: